Trofinetide is a tripeptide comprising of glycine, 2-methyl-L-proline, and L-glutamic acid joined in sequence by peptide linkages. It is the first and only treatment approved by the FDA specifically indicated for Rett syndrome in adults and pediatric patients two years of age and older. Among its listed roles, it functions as a neuroprotective agent and an anti-inflammatory agent. It is a tripeptide, a pyrrolidinecarboxamide, a primary amino compound, a secondary carboxamide, a tertiary carboxamide and a dicarboxylic acid. Functionally, it is related to L-glutamic acid and a glycine. The directory classifies it as a commercial API with a peptide source/manufacturing origin. Other names for this substance include Daybue, trofinetidum and glycyl-alpha-methyl-L-prolyl-L-glutamic acid. Its PubChem CID is 11318905.
Trofinetide
| CAS No | 853400-76-7 |
|---|---|
| Molecular Formula | C13H21N3O6 |
| Molecular Weight | 315.32 g/mol |
| Synonyms | (2S)-2-[[(2S)-1-(2-aminoacetyl)-2-methylpyrrolidine-2-carbonyl]amino]pentanedioic acid |
Zoho Contact Form
"*" indicates required fields
Frequently Asked Questions
Trofinetide is a tripeptide comprising of glycine, 2-methyl-L-proline, and L-glutamic acid joined in sequence by peptide linkages. It is the first and only treatment approved by the FDA specifically indicated for Rett syndrome in adults and pediatric patients two years of age and older.
The listed CAS number is 853400-76-7.
The listed molecular formula is C13H21N3O6.
The listed molecular weight is 315.32 g/mol.
(2S)-2-[[(2S)-1-(2-aminoacetyl)-2-methylpyrrolidine-2-carbonyl]amino]pentanedioic acid.
The source lists Daybue, trofinetidum and glycyl-alpha-methyl-L-prolyl-L-glutamic acid.